Supernus Pharmaceuticals (SUPN) Form 8-K Summary (Nov 4, 2025)

Supernus furnished Q3 2025 financial results (Item 2.02) via press release (Exhibit 99.1).

The most critical update is a supply constraint impacting the drug ONAPGO due to stronger-than-expected demand (Item 7.01).

Key investor implications:

• The Company is pausing new patient initiations for ONAPGO to prioritize current patients.
• Management is actively working to resolve inventory shortages and resume new starts.
• This disclosure suggests potential immediate limitations on revenue growth related to this specific p